Wang et al. demonstrated that treatment with shikonin resulted in a reduction in serum lactate and HMGB1 levels and protected against cecal ligation and puncture (CLP)-induced sepsis and in a murine model of LPS-induced endotoxemia [133] (Figure 4A). Here, HMGB1 is linked to serum lipopolysaccharide activity.